BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 3804368)

  • 1. A biological approach to optimize interferon treatment in hairy cell leukemia.
    Gastl G; Aulitzky W; Tilg H; Nachbaur K; Troppmair J; Flener R; Huber C
    Immunobiology; 1986 Sep; 172(3-5):262-8. PubMed ID: 3804368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of clinical efficacy and toxicity of conventional and optimum biological response modifying doses of interferon alpha-2C in the treatment of hairy cell leukemia: a retrospective analysis of 39 patients.
    Gastl G; Werter M; De Pauw B; Nerl C; Aulitzky W; von Lüttichau I; Tilg H; Thaler J; Lang A; Abbrederis K
    Leukemia; 1989 Jun; 3(6):453-60. PubMed ID: 2725061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Results of a phase II study on the treatment of hairy cell leukemias with various doses of alpha-2-recombinant interferon].
    Aulitzky W; Gastl G; Troppmair J; Tilg H; Abbrederis K; Nerl C; Flener R; Rokos H; Huber C
    Acta Med Austriaca; 1985; 12(5):115-21. PubMed ID: 3832745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell leukemia.
    Huber C; Aulitzky W; Tilg H; von Lüttichau I; Troppmair J; Nachbauer K; Gastl G
    Leukemia; 1987 Apr; 1(4):355-7. PubMed ID: 3669762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interferon-alpha in the treatment of hematologic neoplasms].
    Aulitzky W; Gastl G; Tilg H; Troppmair J; Leiter E; Geissler D; Flener R; Huber C
    Wien Med Wochenschr; 1986 Apr; 136(7-8):172-81. PubMed ID: 3524022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of patient monitoring in clinical cytokine trials: use of serum markers to define biologically active doses.
    Huber C; Herold M
    Cancer Surv; 1989; 8(4):809-15. PubMed ID: 2518331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IFN-beta induced biochemical and immunological modifications in hairy cell leukemia patients.
    Liberati AM; Schippa M; Portuesi MG; Grazia Proietti M; De Angelis V; Ferrajoli A; Cinieri S; Di Clemente F; Palmisano L; Berruto P
    Haematologica; 1991; 76(5):375-82. PubMed ID: 1806440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies.
    Steis RG; Smith JW; Urba WJ; Clark JW; Itri LM; Evans LM; Schoenberger C; Longo DL
    N Engl J Med; 1988 Jun; 318(22):1409-13. PubMed ID: 3367950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The UCLA experience with type I interferons in hairy cell leukemia.
    Glaspy JA; Jacobs AD; Golde DW
    Leukemia; 1987 Apr; 1(4):323-6. PubMed ID: 3312839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant alpha-2 interferon in the treatment of hairy cell leukemia.
    Thompson JA; Brady J; Kidd P; Fefer A
    Cancer Treat Rep; 1985; 69(7-8):791-3. PubMed ID: 4016788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of alpha-interferon in the treatment of patients with hairy cell leukemia].
    Gotić M; Rolović Z; Vuković S; Elezović I; Tomić D
    Srp Arh Celok Lek; 1990; 118(7-8):277-84. PubMed ID: 2097776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The U.K. experience with human lymphoblastoid interferon in HCL: a report of the first 50 cases.
    Worman CP; Catovsky D; Cawley JC; Bevan PC; Bottomley JM; Nethersell AB
    Leukemia; 1987 Apr; 1(4):320-2. PubMed ID: 3669754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose interferon alfa-2b in the treatment of hairy cell leukemia.
    Moormeier JA; Ratain MJ; Westbrook CA; Vardiman JW; Daly KM; Golomb HM
    J Natl Cancer Inst; 1989 Aug; 81(15):1172-4. PubMed ID: 2746669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha interferon for induction of remission in hairy-cell leukemia.
    Quesada JR; Reuben J; Manning JT; Hersh EM; Gutterman JU
    N Engl J Med; 1984 Jan; 310(1):15-8. PubMed ID: 6689734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hairy cell leukemia with increasing doses of recombinant alpha A interferon.
    Holmes R; Schwarz MA; Whiteside MG; Firkin FC
    Aust N Z J Med; 1988 Jun; 18(4):557-62. PubMed ID: 3196242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid improvement in a terminal case of hairy cell leukemia treated with a new human recombinant interferon, IFN-alpha-C.
    Aderka D; Levo Y; Rahmani R; Mory Y; Vaks B; Horowitz O; Doerner T; Shoham J; Wallach D; Revel M
    Isr J Med Sci; 1985 Dec; 21(12):977-81. PubMed ID: 4093298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro induction of proteins by alpha-interferon in hairy cell leukemia.
    Samuels BL; Golomb HM; Brownstein BH
    Cancer Res; 1986 Aug; 46(8):4151-5. PubMed ID: 3731082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hairy cell leukaemia with recombinant alpha interferon.
    Romeril KR; Carter JM; Green GJ; Beard ME; Heaton DC; Newhook CH; Gibbons SS; Reddy J
    N Z Med J; 1989 Apr; 102(866):186-8. PubMed ID: 2652008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia.
    Steis RG; Smith JW; Urba WJ; Venzon DJ; Longo DL; Barney R; Evans LM; Itri LM; Ewel CH
    Blood; 1991 Feb; 77(4):792-8. PubMed ID: 1704264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hairy cell leukemia with alpha interferons.
    Quesada JR; Gutterman JU; Hersh EM
    Cancer; 1986 Apr; 57(8 Suppl):1678-80. PubMed ID: 3948137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.